Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2003

View Archived Issues

Milnacipran reduces pain in depressed and nondepressed FMS patients

Novacea licenses North American rights to AQ4N

Oxigene expands ophthalmology R&D program

Combidex improves the accuracy of MRI in the diagnosis of metastatic cancer

DB-289 safe and effective in patients with first-stage sleeping sickness

Clinical trials confirm good safety profile of yellow fever vaccine; BLA filed

Phase II results for Itax confirm earlier safety and efficacy findings

Ketek launched in Japan

Generex and Acertus to develop oral recombinant human growth hormone

Canadian notice of noncompliance for Circadin

Finacea approved in E.U. as topical treatment of papulopustular rosacea

Targent acquires dibromodulcitol

CSL to acquire Aventis Behring

Chugai launches Pegasys in Japan

Japanese rights to bevacizumab and pertuzumab licensed to Chugai

Disappointing results for HuMax-CD4 in phase IIb psoriasis trial

Start of phase I safety study of Genz-29155 announced by Genzyme

Niaspan and Advicor filed for marketing approval in Canada

Independent committee recommends early end to phase III Velcade trial

Enrollment completed in phase II study of ThGRF in HIV-related lipodystrophy

Immunosuppressant series patented by Sankyo

Valera files Vantas NDA

Beta-lactamase inhibitors prepared by Wyeth team

New combinations for the treatment of cardiac arrhythmias

Merck scientists synthesize new chemokine receptor modulators

Caspase inhibitors designed by Korean researchers

Neurogen identifies imidazole-based GABA-A receptor ligands

New findings on structure and function of prostate-specific membrane antigen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...